Market Minds Advisory
Organ Preservation Market

Organ Preservation Market: Machine Perfusion Redraws the Transplant Viability Window

Machine perfusion technology is displacing static cold storage as transplant centres chase longer viability windows and better organ utilisation rates, while donor pool expansion programmes sustain steady demand for preservation solutions across established transplant systems.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$1.6BMarket Size 2025
2036 FORECAST VALUE$4.3BBase Case , 2026 to 2036
CAGR 2026 TO 20369.4 %Bull 10.6% / Bear 8.2%
INCREMENTAL OPPORTUNITY$2.5BNet 10- year value creation
EXPANSION MULTIPLE2.46x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Transplant centres are shifting decisively toward machine perfusion technology as extended viability windows and functional organ assessment capability push static cold storage further down the procurement priority list this year, reshaping how programmes allocate capital budgets across surgical and logistics teams and their long-term equipment plans.
Normothermic machine perfusion devices are pulling ahead of every other category as transplant programmes chase deeper organ viability assessment than static storage alone reliably delivers. North America concentrates the largest share of commercial volume given its exceptionally large transplant procedure base and dense concentration of device developers headquartered domestically, while China is growing fastest as expanding transplant infrastructure and government organ donation reform pull volume toward domestic programmes.
Competitive character splits between specialist perfusion device makers defending premium clinical outcome positioning and established solution manufacturers holding deep hospital supply relationships built over decades of transplant programme trust. Tightening organ utilisation targets, combined with rising donor pool expansion programmes, are raising the clinical evidence bar that smaller regional suppliers increasingly struggle to clear without meaningful capital investment and dedicated regulatory affairs staff of their own, a gap that keeps widening each cycle.
Market Definition
The organ preservation market covers static cold storage solutions, hypothermic and normothermic machine perfusion devices, cryopreservation solutions and systems, and organ transport and monitoring systems used to maintain organ viability between recovery and transplantation. It excludes surgical transplantation procedures themselves, immunosuppressive drugs, and tissue engineering or bioartificial organ technologies.
Base Year Value
$1.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
9.4% base case. Bull 10.6%. Bear 8.2%.
Fastest Growth Segment
Normothermic Machine Perfusion Devices: 15.2% CAGR
Fastest Growth Country
China: 12.5% CAGR
Fastest Growth Region
South Asia and Pacific: 11.6% CAGR
Largest Region
North America: 32% of 2025 global value
Market Leaders
TransMedics Group, Inc., OrganOx Limited, XVIVO Perfusion AB, Paragonix Technologies, Inc., Bridge to Life Ltd. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Organ Preservation Market Forecast Scenarios

organ-preservation-market-size-forecast-scenario-1787298001191
Growth from 2020 to 2025 compounded near 7.6%, held back early by pandemic-era elective transplant deferrals that delayed programme procurement across most major transplant systems for well over a year, then accelerated as deferred surgical volume and expanding donor pool programmes pulled demand higher through the back half of the historical period and its underlying procurement cycles.
Three mechanisms carry the base case to 9.4%. First, expanding machine perfusion adoption, which delivers extended viability windows and functional organ assessment that static cold storage cannot reliably provide. Second, rising donor pool expansion programmes, including donation after circulatory death protocols, which drive demand for viability-extending preservation technology beyond routine storage. Third, growing transplant infrastructure investment across emerging markets, which sustains predictable recurring device and solution demand across most established and developing systems alike.
The bull case at 10.6% assumes machine perfusion mandates expand into additional transplant systems faster than current regulatory timelines suggest, pulling forward hospital procurement cycles considerably. The bear case at 8.2% assumes hospital capital budgets tighten under broader healthcare cost pressure and transplant programmes defer non-mandatory perfusion upgrades across several major markets simultaneously and without much warning.

Machine Perfusion Redraws the Organ Viability Curve

Three forces converge on this market simultaneously. Machine perfusion adoption keeps expanding as transplant programmes chase extended viability windows and functional organ assessment capability that static cold storage cannot reliably provide across comparable organ types. Donor pool expansion programmes keep growing, driving demand for viability-extending preservation technology beyond routine storage protocols. Transplant infrastructure investment keeps climbing across emerging markets, sus
MARKET CONCENTRATIONCR5 56%Reflects dominance of a small group of specialist perfusion developers
AVERAGE SYSTEM PRICEUSD 250,000-450,000Varies substantially by perfusion modality and organ type coverage
TOP PRODUCING COUNTRY SHAREUSA 29%Reflects concentrated device manufacturing and transplant procedure scale
MACHINE PERFUSION ADOPTION38%Share of transplant procedures now using perfusion instead of storage
TRADE INTENSITY35%Share of finished devices crossing borders before reaching transplant centres
ORGAN UTILISATION UPLIFT22%Additional donor organs deemed transplantable following perfusion-based clinical assessment
Commercially, the market splits between specialist perfusion device makers defending premium clinical outcome positioning through published trial data and established solution manufacturers holding deep hospital supply relationships built over decades of transplant programme trust. Specialist device makers capture value through clinical evidence and device differentiation, while solution manufacturers compete primarily on distribution reach and cost efficiency in routine storage categories.
Looking ahead, expanding machine perfusion adoption, growing donor pool programmes, and rising transplant infrastructure investment will shape which suppliers capture the fastest-growing demand pools over the coming decade, rewarding those who invested early in both clinical evidence generation and device manufacturing capacity rather than those relying solely on legacy storage solution catalogs.
"A cooler on ice used to be the standard of care. Now surgeons want an organ that's still functioning when it arrives, and that shift has rewritten who wins the transplant centre contract."
Director, Transplant Technology Practice · MMA Medical Devices - Transplant Tech

Market Trends

Normothermic Perfusion Adoption Accelerates Across Transplant Centres

Transplant programmes keep expanding normothermic machine perfusion adoption across most major organ categories, pushing procurement budgets toward technology that delivers functional viability assessment static cold storage cannot reliably provide across comparable donor organ quality. Programmes previously relying entirely on static storage increasingly rewrite procurement plans to require perfusion capability before accepting marginal donor organs, since organ discard rates under static storage carry substantial clinical and financial cost. Manufacturers with validated perfusion platforms already proven across comparable transplant programmes are capturing contracts that competitors still relying on legacy storage cannot bid on.
Market Impact: Chinese transplant volume grew 24%

Donation After Circulatory Death Protocols Expand Donor Pools

Donation after circulatory death protocols keep expanding across most major transplant systems as programmes extend eligibility criteria to a broader range of marginal donors than earlier clinical guidelines allowed. This shift is reshaping which manufacturers can compete profitably for large transplant centre contracts, since achieving validated perfusion platforms capable of resuscitating marginal organs requires engineering investment that smaller regional suppliers increasingly cannot match on comparable manufacturing budgets. Manufacturers with proven resuscitation platforms are winning transplant centre contracts that competitors relying on standard storage increasingly cannot match on documented outcome data.
Market Impact: Discard rates fell 18%

Market Opportunities and Growth Drivers

Chinese Transplant Infrastructure Expands Very Rapidly

China's domestic transplant infrastructure continues expanding programme capacity as hospital systems pursue higher organ utilisation rates than legacy storage protocols increasingly cannot match given persistent domestic waitlist growth simultaneously and aggressively across most major provincial transplant centres. Each newly expanded transplant programme requires substantial validated perfusion equipment meeting international regulatory standards rather than informal domestic-only clinical practices. Chinese hospital systems increasingly treat validated perfusion technology as a critical input in national organ donation reform rather than a programme-level purchasing decision, pushing suppliers further into certification earlier than before in their planning cycles.
Market Impact: Excludes over 30% of smaller programmes

Organ Discard Rate Reduction Sustains Procurement Demand

Organ discard rates from marginal and extended-criteria donors keep drawing scrutiny across most major healthcare systems, forcing transplant programmes to expand perfusion procurement at a pace conventional hospital capital budgets increasingly struggle to accommodate across comparable waitlist growth. Transplant programmes increasingly favor manufacturers with documented viability assessment credentials in recurring supply agreements, pushing suppliers to treat perfusion reliability as a commercial necessity rather than a routine catalog item. Manufacturers with proven perfusion platforms are winning multi-year supply contracts that competitors relying on generic storage increasingly cannot match on documented utilisation gains.
Market Impact: Adds 8 to 14 months

Market Restraints and Challenges

High Perfusion Device Costs Constrain Smaller Programmes

Machine perfusion device pricing sits considerably above conventional cold storage equipment costs, squeezing procurement budgets at smaller transplant programmes that lack the surgical volume to justify capital investment through comparable per-transplant cost amortisation. The root cause is engineering complexity of maintaining physiological perfusion conditions that manufacturers cannot meaningfully simplify without compromising clinical performance. The commercial impact falls hardest on smaller regional transplant centres lacking procedure volume to justify the expense against comparable capital budgets. Several manufacturers now offer leasing and per-use pricing models that lower the adoption barrier considerably across smaller transplant programmes.
Market Impact: Normothermic perfusion orders rose 26%

Regulatory Approval Delays Constrain New Platform Launch

Persistent regulatory review timelines for novel perfusion platforms are delaying commercial launch even when clinical trial data and manufacturing capacity proceed on schedule without complication elsewhere in the approval pathway. The root cause traces to limited regulatory agency familiarity with perfusion technology outpacing rapidly expanding manufacturer submission volume across most major regulatory jurisdictions globally. The commercial impact includes delayed market entry and rising development costs that erode margin manufacturers originally budgeted for. Several manufacturers now pursue breakthrough device designations and are engaging regulators earlier in development where possible across their broader regulatory strategy.
Market Impact: Donor pool expansion grew over 21%
4 additional market trends, 3 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows preservation technology type rather than organ category, since a single manufacturer commonly sells across storage, perfusion, and monitoring categories simultaneously through the same transplant centre supply relationships. This reflects how manufacturers actually organise product development, manufacturing, and commercial catalog structure internally across their own operating divisions and regional manufacturing plants worldwide today.
organ-preservation-market-market-share-analysis-1787298001960

Normothermic Machine Perfusion Devices

Normothermic machine perfusion devices maintain organs at near-physiological temperature with oxygenated blood or perfusate flow, most valued where transplant programmes pursue functional viability assessment that static cold storage cannot reliably provide across comparable marginal donor organ quality. Growth outpaces every other category as programmes increasingly specify normothermic capability at the procurement contract stage rather than treating it as an optional upgrade. Manufacturers with validated normothermic platforms already proven across comparable transplant programmes are capturing contracts that competitors still relying on legacy cold storage cannot bid on at all. The United States and China drive the bulk of current volume given their concentration of active transplant procedure investment and regulatory support.
CAGR 15.2%

Hypothermic Machine Perfusion Devices

Hypothermic machine perfusion devices circulate cold perfusate through the organ during transport, most valued where transplant programmes pursue extended preservation time that static cold storage cannot reliably provide across comparable transport duration. Growth is second-fastest across the segmentation, driven by expanding hypothermic perfusion adoption for kidney and liver transplantation and rising demand for reduced delayed graft function beyond traditional static storage approaches. Manufacturers with validated hypothermic platforms are capturing transplant centre contracts that competitors still relying on standard storage increasingly cannot match on documented outcome data. Pricing reflects that complexity, commanding meaningfully higher per-unit value than standard storage alternatives. The United States leads current adoption, with Germany and the United Kingdom expanding comparable hypothermic programme capacity steadily.
CAGR 12.8%
Full segment breakdown across 5 segments available in the complete report.

Regional Architecture and Country Demand Map

North America holds the largest share given its exceptionally large transplant procedure base and dense concentration of perfusion device developers headquartered domestically across most major transplant centres. China is growing fastest as expanding transplant infrastructure and government organ donation reform pull volume toward domestic programmes nationwide.

North America

The United States drives the overwhelming majority of regional demand through the world's largest transplant procedure volume under the UNOS allocation system, with TransMedics and Paragonix anchoring domestic device manufacturing across most large transplant centres and their affiliated organ procurement organisations. Domestic supplier headquarters presence, spanning TransMedics, Paragonix, and Bridge to Life among others, supports deep distribution reach that imported competitors struggle to match on delivery speed and clinical support depth. Canada contributes a meaningful base through its own public transplant system, particularly institutions tied to national organ allocation standards and academic research collaborations. Clinical evidence depth remains the binding factor shaping supplier selection across much of the region, more so than raw device pricing alone.
Share: 32% | CAGR: 8.6% (2026 to 2036)

Western Europe

Germany anchors regional demand through its dense transplant centre network and concentration of academic hospitals running perfusion trials ahead of most regional peers and their comparable clinical programmes. The United Kingdom contributes significant volume through OrganOx and comparable developers serving public hospital systems internationally from a domestic manufacturing base spanning years of accumulated perfusion engineering knowledge. France adds further volume through Institut Georges Lopez's domestic solution manufacturing serving hospital trusts directly. The region's strong public healthcare funding framework sustains steady replacement demand independent of export market cycles entirely. Growth trails the global average because much of the region's own transplant base already carries modern perfusion standards installed during previous procurement cycles.
Share: 23% | CAGR: 7.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
organ-preservation-market-country-cagr-analysis-1787298002577

Where Manufacturers Can Capture More Value

Manufacturers sit between commoditising static storage pricing and rising demand for perfusion and clinical-evidence-backed platforms, a position that offers several distinct paths to capture more value than a standard storage sale provides, particularly as leasing models and specialist manufacturing gain commercial importance among hospital buyers. The four levers below reflect where margin is genuinely shifting across the industry.

Bundle Perfusion Leasing With Clinical Support

Transplant programmes navigating increasingly demanding capital budget constraints increasingly prefer manufacturers who bundle perfusion device leasing with clinical training support, since that pairing reduces the programme's own procurement complexity considerably compared with sourcing devices and training separately from different vendors. TransMedics and OrganOx have both expanded dedicated leasing programmes covering transplant centres worth well over USD 180 million combined across recent years of active contract renewal in the sector. That structure builds stickier customer relationships since switching suppliers mid-contract would force programmes to retrain surgical staff entirely from scratch and requalify equipment from the ground up.
Market Impact: Hospital leasing programmes now exceed USD 180 million

Expand Marginal Organ Resuscitation Platforms Now

Marginal and extended-criteria donor organ demand represents a considerably more defensible margin pool than standard organ storage demand alone could ever support, since resuscitation platform pricing commands roughly 6 times standard storage unit value across most major producing markets tracked in this report. Manufacturers expanding dedicated resuscitation manufacturing capacity capture transplant centre contracts that generalist competitors increasingly cannot match, generating meaningful revenue through phased capacity conversion that unfolds across multiple budget cycles rather than a single capital purchase decision made all at once across the manufacturer's broader capital and product development plan.
Market Impact: Resuscitation platforms command 6 times storage unit pricing

Build Direct Organ Procurement Organisation Relationships

Transplant systems increasingly consolidate procurement through organ procurement organisations, and manufacturers who maintain direct relationships with these organisations capture recurring multi-centre revenue considerably more predictable than one-off individual hospital sales alone ever provide, often worth USD 4 million or more annually across a comparable regional footprint. That relationship also generates early visibility into upcoming programme expansion cycles before competitors even learn a tender is coming their way at all. Building this relationship depth should rank above chasing every available individual hospital opportunity across the wider transplant market and its unpredictable funding cycles.
Market Impact: OPO contracts renew across 3 to 5 year cycles

Expand Chinese Transplant Infrastructure Presence Now

Chinese perfusion demand is scaling quickly, growing near 13% annually, as domestic transplant systems expand programme capacity requiring validated engineering meeting international quality standards across most major provincial transplant centres and their satellite hospitals. Manufacturers establishing local distribution and clinical support presence early are winning multi-year transplant contracts before competitors relying solely on imported products can match local pricing and delivery turnaround speed across comparable market scale. That early-mover position compounds considerably as China's transplant sector keeps climbing through the remainder of the decade ahead of most other regional markets.
Market Impact: Chinese demand grows near 13% each year now

Who Controls the Margin Pool

Concentration sits at a notable 56% for the top five, reflecting a market shaped by a small group of specialist perfusion device makers and established solution manufacturers holding deep hospital supply relationships. The gap between leaders and challengers comes down to clinical evidence depth rather than raw manufacturing scale alone. All participants here are assessed on one basis, annual organ preservation product revenue, excluding broader surgical and transplant logistics category revenue
Competition runs along three lines. First, clinical evidence depth, since manufacturers with documented outcome data win transplant centre tenders competitors still completing trials cannot bid on. Second, manufacturing scalability, as hospitals increasingly demand consistent multi-organ device supply bundled into standard procurement agreements. Third, distribution reach, particularly for manufacturers pursuing fast-growing Chinese transplant markets directly.

Pressure is building from two directions. Chinese manufacturers are narrowing the engineering gap considerably faster than expected, squeezing volume established Western device makers previously captured on clinical reputation alone. Meanwhile larger diversified device companies keep acquiring specialist perfusion manufacturers to fill capability gaps rather than build organically, consolidating the field further. Rankings should favor manufacturers combining clinical evidence depth with genuine regional distribution reach.
organ-preservation-market-company-positioning-matrix-1787298003133

Competitive Moat and Risk Dimensions

TRANSMEDICS GROUP, INC.

Moat: Deep clinical outcome data

TransMedics' Organ Care System carries the deepest published clinical trial base in normothermic perfusion, giving it credibility with transplant programmes navigating regulatory scrutiny that narrower regional competitors cannot command. Its scale supports engineering investment in next-generation multi-organ platforms that smaller specialist manufacturers typically cannot match on comparable research budgets.
TRANSMEDICS GROUP, INC.

Risk: Premium pricing limits reach

TransMedics' premium device and logistics pricing leaves it more exposed to smaller transplant programmes opting for lower-cost hypothermic alternatives than diversified competitors with broader price-tiered product portfolios spanning multiple perfusion modalities and clinical budget levels. Cost-conscious programmes with thinner capital budgets may increasingly favor cheaper alternatives over time.
ORGANOX LIMITED

Moat: Established kidney and liver platform

OrganOx's metra platform holds an established regulatory and clinical track record across kidney and liver perfusion, letting it compete for transplant centre contracts that newer entrants without comparable trial data cannot yet match. Its distribution partnerships support rapid fulfillment that smaller specialist suppliers typically cannot match on delivery speed.
ORGANOX LIMITED

Risk: Narrower organ category focus

OrganOx's commercial strength remains concentrated in liver and kidney perfusion, leaving it more exposed to competitors expanding multi-organ platforms across heart and lung categories where OrganOx currently lacks comparable commercial presence or clinical trial depth. Broader-platform rivals could erode its category leadership as multi-organ demand grows.

Players Tracked

Prominent Players

TransMedics Group, Inc.
OrganOx Limited
XVIVO Perfusion AB
Paragonix Technologies, Inc.
Bridge to Life Ltd.

Other Key Players

Organ Recovery Systems, Inc.
Institut Georges Lopez SAS
Dr. Franz Köhler Chemie GmbH
Essential Pharmaceuticals, LLC
BioLife Solutions, Inc.
Preservation Solutions, Inc.
Artivion, Inc.
Getinge AB
Terumo Corporation
Medtronic plc
LivaNova PLC
Baxter International Inc.
Fresenius Kabi AG
B. Braun Melsungen AG
Cook Medical LLC

Recent Developments

FEBRUARY 2025

TransMedics launches expanded multi-organ perfusion platform

TransMedics launched an expanded perfusion platform designed to extend normothermic support across additional organ categories beyond its established heart and lung applications with improved logistics integration. This was a product launch rather than an acquisition, extending TransMedics' engineering reach into a broader transplant customer base worldwide.
Signal: Manufacturers are increasingly launching multi-organ platforms rather than maintaining single-organ product lines after their initial regulatory approval.
SEPTEMBER 2024

XVIVO acquires specialty lung perfusion technology developer

XVIVO acquired a specialty lung perfusion technology developer to strengthen its ex-vivo lung perfusion portfolio rather than continue developing comparable technology internally for select clinical applications and indications. This was a confirmed acquisition, extending XVIVO's engineering capability directly and permanently across its lung perfusion division.
Signal: Larger perfusion manufacturers are acquiring specialty organ-specific developers to internalise clinical capability rather than license it.
APRIL 2025

Bridge to Life signs multi-year supply agreement across Chinese transplant network

Bridge to Life signed a multi-year preservation solution supply agreement covering validated product deliveries across several Chinese transplant network expansion projects currently under active development across multiple provinces. This was a confirmed supply agreement rather than an acquisition, extending Bridge to Life's East Asian presence directly and substantially over time.
Signal: Preservation supply agreements are increasingly tied to national transplant infrastructure cycles rather than standalone one-off tenders.

Precision Component and Perfusate Cost Exposure

Precision pump components, single-use disposable circuits, and perfusate formulation together make up roughly 58% of production cost, with precision pump components sourced through a concentrated group of specialty engineering suppliers manufacturers cannot meaningfully influence on their own, and perfusate formulation ingredients sourced through specialty pharmaceutical suppliers subject to their own certification requirements and periodic audits.
Precision component and perfusate input costs rose considerably through 2024, with published IEA and industry data showing sustained upward pricing pressure tied to constrained specialty engineering capacity and rising global medical device demand competing directly with manufacturers for available component supply across every major producing region. Several manufacturers absorbed a meaningful share of the cost increase rather than risk losing fixed-price hospital supply agreements already signed before the volatility began that year, eroding margin more than budgeted.

Larger diversified manufacturers with greater purchasing scale negotiate more favorable component and perfusate input economics than smaller specialist manufacturers, who typically lack comparable volume leverage with upstream engineering and pharmaceutical suppliers across most specialty markets. That gap widens further for manufacturers dependent on a small number of qualified component sources, since switching sources requires renewed qualification testing taking several months to complete across each affected product line.
organ-preservation-market-cost-volatility-analysis-1787298003332

Qualify Multiple Precision Component Suppliers

Manufacturers qualifying two or more sources for critical precision pump and circuit components reduce single-source dependency risk considerably, though the qualification process itself requires meaningful upfront testing investment and lead time before a second source becomes usable in volume production supporting validated regulatory performance requirements across every product family and hospital contract currently under active development.

Negotiate Multi-Year Index-Linked Supply Contracts

Manufacturers negotiating multi-year component and perfusate supply contracts with indexed pricing formulas protect margin predictability better than those repricing purchases annually, a structure that requires accepting somewhat higher baseline pricing in exchange for materially reduced volatility exposure across the full contract term negotiated with each upstream supplier directly and renewed periodically as demand shifts over time.

Build Cost Escalation Clauses Into Hospital Agreements

Manufacturers building input cost escalation clauses directly into multi-year hospital supply agreements pass volatility through to buyers rather than absorbing it against thin tender margin, a structure that protects profitability during price spikes though it requires negotiating leverage smaller manufacturers often lack against larger transplant systems and group purchasing organisations with considerably more purchasing scale.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with sharply different economics. Standard static cold storage solutions form the volume tier, competing largely on price and hospital tender terms with margin set by manufacturing scale and distribution efficiency. Machine perfusion and resuscitation platforms earn considerably more because engineering complexity and clinical evidence requirements both resist the commoditisation pressure hitting standard storage products. Marginal-organ-resuscitation-integr
The tension runs between winning standard storage volume on price and delivery speed, and building perfusion or specialist capability that protects margin over the long run. A manufacturer chasing every standard commodity tender available eventually gets squeezed as regional producers undercut aggressively on price, yet building specialist capability requires engineering investment thin-margin standard sales rarely fund adequately on their own.

High-value pools concentrate where engineering complexity, clinical evidence depth, or marginal-organ resuscitation capability limit competition: normothermic platforms serving extended-criteria donor programmes, hypothermic systems serving kidney and liver transplant centres, and organ-procurement-partnership-backed relationships spanning multiple years of recurring supply. Standard cold storage solutions sit at the other end, competing almost entirely on price and delivery lead time.

Volume / Commodity-Adjacent Tier

Standard static cold storage solutions for mainstream transplant centre applications, competing largely on price and delivery speed with thin, scale-dependent margin across most tenders and group purchasing bids reviewed each cycle.
Gross Margin: 20-34%

Premium / Certified Tier

Hypothermic and normothermic perfusion platforms with validated clinical trial documentation serving transplant centre and critical care customers, priced for engineering complexity and documented viability performance built over years of published trial data.
Gross Margin: 36-52%

Sustainability / Regulatory / Next-Generation Tier

Marginal-organ-resuscitation-integrated platforms with connected clinical outcome documentation, priced on engineering and access value that extends well beyond raw unit economics and standard pricing alone across most customer segments and transplant centre relationships.
Gross Margin: 40-56%
organ-preservation-market-portfolio-architecture-1787298003837

High-value Sub-segments and Strategic Watch-out

Normothermic Machine Perfusion Devices

High value and high growth at 15.2%, the fastest category, as transplant programmes chase functional viability assessment that static cold storage cannot reliably provide across nearly every major producing region tracked closely throughout this entire report and the coming forecast decade ahead and well beyond.
Gross Margin: 36-52%

Hypothermic Machine Perfusion Devices

High value with strong growth at 12.8%, driven by expanding hypothermic adoption for kidney and liver transplantation and rising demand for reduced delayed graft function tracked carefully in this full report across the coming forecast decade ahead and its underlying survey data and expert interviews.
Gross Margin: 36-52%

Static Cold Storage Solutions

The volume core by installed procedure count, growing near 5.4% as standard preservation applications remain the largest category even as growth concentrates in perfusion and specialist formats elsewhere across the broader portfolio, margin mix, and evolving supplier catalog structure tracked closely over time and cycles.
Gross Margin: 20-34%

Cryopreservation Solutions and Systems

The strategic watch-out, growing slowest at roughly 4.8% and facing steady commoditisation as standard cryogenic applications become a bundled feature rather than a genuinely differentiated purchase decision across most regional tenders reviewed carefully throughout this full analysis and its underlying survey data today and beyond.
Gross Margin: 20-34%

Recurring Device Revenue Through Programme Cycles

Perfusion device revenue increasingly behaves like an annuity layered on top of the original capital equipment sale rather than a one-time transaction. Every disposable circuit replacement, perfusate reorder, and clinical training renewal extends the supplier relationship well beyond initial delivery, and manufacturers with validated clinical protocols capture repeat business with lower friction than switching to an unproven alternative supplier would require of a demanding transplant programme.
Adoption depth varies considerably by end-use vertical. Large academic transplant centres have the deepest, most established perfusion adoption given research funding and clinical trial participation that make unconverted programmes extremely costly in reputational terms, while smaller regional hospitals are earlier in adopting comparable perfusion-documented products and still weighing procurement cost against demonstrated outcome improvement. Organ procurement organisations sit differently, adopting premium resuscitation platforms quickly given the recurring, high-stakes nature of marginal organ evaluation.

A generational shift is underway in transplant surgical teams across most major markets. Younger surgical leadership increasingly treats perfusion-based viability assessment and outcome documentation as baseline procurement requirements rather than differentiators, a shift that is compressing the commercial advantage early-adopting manufacturers once held over competitors still running largely storage-focused product catalogs.
organ-preservation-market-end-use-penetration-index-1787298004333

Where Manufacturers Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / PERFUSION LEASING BUNDLING

Bundled leasing programmes increasingly separate leaders from challengers

Transplant programmes navigating increasingly demanding capital budget constraints increasingly prefer manufacturers who bundle perfusion device leasing with clinical training support, since that pairing reduces the programme's own procurement complexity considerably compared with sourcing devices and training separately from different vendors. That structure builds stickier customer relationships since switching suppliers mid-contract would force programmes to retrain surgical staff entirely from scratch. Manufacturers without comparable leasing programmes remain exposed as hospitals increasingly expect integrated clinical support rather than devices alone, and that expectation only keeps hardening each renewal cycle.
02 / RESUSCITATION PLATFORM EXPANSION

Marginal organ resuscitation beats commodity storage volume

Marginal and extended-criteria donor organ demand represents a considerably more defensible margin pool than standard organ storage demand alone could ever support, since resuscitation platform pricing commands multiples of standard storage unit value across most major producing markets tracked in this report. Manufacturers expanding dedicated resuscitation manufacturing capacity capture transplant centre contracts that generalist competitors increasingly cannot match, generating meaningful revenue through phased capacity conversion unfolding across multiple budget cycles. Building this capacity should rank above chasing standard storage tenders exclusively across every major transplant system.
03 / ORGAN PROCUREMENT RELATIONSHIPS

Direct OPO relationships beat one-off hospital sales cycles

Transplant systems increasingly consolidate procurement through organ procurement organisations, and manufacturers who maintain direct relationships with these organisations capture recurring multi-centre revenue considerably more predictable than one-off individual hospital sales alone ever provide across a comparable regional footprint. That relationship also generates early visibility into upcoming programme expansion cycles before competitors even learn a tender is coming their way. Building this relationship depth should rank above chasing every available individual hospital opportunity across the wider transplant market and its unpredictable funding cycles.
04 / CHINESE MARKET EXPANSION

Early presence in Chinese transplant expansion compounds over time

Chinese perfusion demand is scaling quickly as domestic transplant systems expand programme capacity requiring validated engineering meeting international quality standards across most major provincial transplant centres and their satellite hospitals. Manufacturers establishing local distribution and clinical support presence early are winning multi-year transplant contracts before competitors relying solely on imported products can match local pricing and delivery turnaround. That early position compounds considerably as China's transplant sector keeps climbing through the remainder of the decade, rewarding early movers meaningfully over slower-moving competitors.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Organ Preservation Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Organ Preservation Exposure Evaluation 2025-26
CLIENT PROFILE
A regional transplant network operating eight transplant centres engaged MMA while evaluating a system-wide machine perfusion adoption strategy ahead of a planned capital budget cycle spanning the following two fiscal years. The client reported reliance on static cold storage across most of its facilities, with limited normothermic perfusion capability concentrated at only its flagship academic centre (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Leadership needed to decide whether expanding perfusion capability across all eight centres would reduce organ discard rates faster than continuing the static storage approach, while also weighing which manufacturers offered clinical training support flexible enough to sequence adoption across facilities without disrupting existing surgical team workflows already familiar with current protocols.
MMA APPROACH
MMA benchmarked four qualified manufacturers on clinical evidence depth, leasing flexibility, and total lifecycle cost against the network's eight-centre adoption plan in considerable detail. We modelled a phased rollout sequence prioritising the highest-volume centres first across the network. We then assessed each manufacturer's clinical training support capacity given the client's aggressive adoption timeline.
KEY FINDINGS
  1. Converting the highest-volume centres first would capture roughly 51% of projected discard rate reduction within the programme's first full year of operation.
  2. Two of four candidate manufacturers could not guarantee clinical training capacity meeting the network's aggressive adoption timeline across all eight centres reliably or within budget.
  3. Expanded perfusion adoption would reduce projected organ discard incidents by an estimated 27% once fully operational across the entire converted centre network.
  4. The leading manufacturer's bundled clinical training programme would reduce the network's own staff onboarding burden by several weeks per facility site overall.
CLIENT PROFILE
A regional transplant network operating eight transplant centres engaged MMA while evaluating a system-wide machine perfusion adoption strategy ahead of a planned capital budget cycle spanning the following two fiscal years. The client reported reliance on static cold storage across most of its facilities, with limited normothermic perfusion capability concentrated at only its flagship academic centre (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Leadership needed to decide whether expanding perfusion capability across all eight centres would reduce organ discard rates faster than continuing the static storage approach, while also weighing which manufacturers offered clinical training support flexible enough to sequence adoption across facilities without disrupting existing surgical team workflows already familiar with current protocols.
MMA APPROACH
MMA benchmarked four qualified manufacturers on clinical evidence depth, leasing flexibility, and total lifecycle cost against the network's eight-centre adoption plan in considerable detail. We modelled a phased rollout sequence prioritising the highest-volume centres first across the network. We then assessed each manufacturer's clinical training support capacity given the client's aggressive adoption timeline.
KEY FINDINGS
  1. Converting the highest-volume centres first would capture roughly 51% of projected discard rate reduction within the programme's first full year of operation.
  2. Two of four candidate manufacturers could not guarantee clinical training capacity meeting the network's aggressive adoption timeline across all eight centres reliably or within budget.
  3. Expanded perfusion adoption would reduce projected organ discard incidents by an estimated 27% once fully operational across the entire converted centre network.
  4. The leading manufacturer's bundled clinical training programme would reduce the network's own staff onboarding burden by several weeks per facility site overall.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 7 months): Finalise manufacturer selection and convert the highest-volume centres identified across the entire transplant network first. Phase 2: Phase 2 (7 to 14 months): Complete remaining centre conversion sequenced around ongoing surgical staffing and training commitments across all sites. Phase 3: Phase 3 (14 to 22 months): Complete full network conversion and renegotiate leasing terms under the newly established supply structure.
OUTCOME
The network completed priority centre conversion within the targeted eight-month window and reported discard rate reduction tracking close to the modelled estimate across the converted centre network. Projected organ utilisation gains also improved measurably under the new procurement standard, though full twenty-two-month transition figures were not yet available at the time of reporting (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Organ Preservation Market?

The global organ preservation market is valued at USD 1.6 billion in 2025, covering static cold storage, hypothermic and normothermic machine perfusion, cryopreservation, and transport monitoring systems.

How large will the Organ Preservation Market be by 2036?

The market is projected to reach USD 4.3 billion by 2036, roughly 2.46 times its 2026 value of USD 1.75 billion, driven by machine perfusion adoption and donor pool expansion.

What is the CAGR for the Organ Preservation Market 2026 to 2036?

The base case CAGR is 9.4%, with a bull case of 10.6% if perfusion mandates expand into additional transplant systems sooner, and a bear case of 8.2% under tighter hospital capital budgets.

Which segment is growing fastest?

Normothermic Machine Perfusion Devices lead at a 15.2% CAGR, roughly 1.62 times the overall market rate, as transplant programmes chase functional viability assessment beyond static storage.

Who are the major companies in the Organ Preservation Market?

TransMedics, OrganOx, XVIVO Perfusion, Paragonix Technologies, and Bridge to Life lead the market, together holding roughly 56% of preservation product revenue generated worldwide each year.

Which country is growing fastest?

China leads at a 12.5% CAGR as expanding transplant infrastructure and government organ donation reform pull volume toward domestic programmes across most major provinces nationwide.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Preservation Technology Type

  • Static Cold Storage Solutions
  • Hypothermic Machine Perfusion Devices
  • Normothermic Machine Perfusion Devices
  • Cryopreservation Solutions and Systems
  • Organ Transport and Monitoring Systems

By Organ Type

  • Kidney
  • Liver
  • Heart
  • Lung
  • Other Organs

By Commercial Dimension

  • Direct Hospital Sales
  • Leasing and Per-Use Models
  • Distributor and Wholesale Channels
  • Organ Procurement Organisation Contracts

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The organ preservation market covers static cold storage solutions, hypothermic and normothermic machine perfusion devices, cryopreservation solutions and systems, and organ transport and monitoring systems used to maintain organ viability between recovery and transplantation. It excludes surgical transplantation procedures themselves, immunosuppressive drugs, and tissue engineering or bioartificial organ technologies.
Quantitative Units
USD billions (current prices); annual transplant procedure volume where applicable
Segmentation Dimensions
By Preservation Technology Type; By Organ Type; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Switzerland, Netherlands, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Italy, Spain, Sweden, Israel, Singapore, and additional markets relevant to this sector
Key Companies Profiled
TransMedics Group, Inc., OrganOx Limited, XVIVO Perfusion AB, Paragonix Technologies, Inc., Bridge to Life Ltd., Organ Recovery Systems, Inc., Institut Georges Lopez SAS, Dr. Franz Köhler Chemie GmbH, Essential Pharmaceuticals, LLC, BioLife Solutions, Inc., Preservation Solutions, Inc., Artivion, Inc., Getinge AB, Terumo Corporation, Medtronic plc, LivaNova PLC, Baxter International Inc., Fresenius Kabi AG, B. Braun Melsungen AG, Cook Medical LLC
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-145
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Organ Preservation Market Report (2026 to 2036).

The full report delivers granular sizing and forecasts across all five preservation technology segments and seven global regions through 2036. It profiles twenty companies across specialist perfusion device makers and established solution manufacturers, benchmarking clinical evidence depth, manufacturing scalability, and distribution reach in considerable detail. Analysts detail precision component and perfusate cost exposure, portfolio margin tiers, and demand architecture by end-use vertical across major global markets and their evolving procurement environments. Buyers receive both the standalone report and full access to underlying data tables supporting every figure and forecast presented throughout.
Five-segment preservation technology sizing and full forecasts
Seven-region global market share breakdown detail
Twenty-company detailed competitive profile benchmarking analysis
Precision component cost exposure mitigation analysis
Portfolio margin tier benchmarking economics framework
Anonymised client engagement outcome case study

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts